DEXATOPIC CREAM Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

dexatopic cream

organon s.a. france - dexamethasone - ΚΡΕΜΑ - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

DEXATOPIC OINTMENT Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

dexatopic ointment

organon s.a. france - dexamethasone - ΑΛΟΙΦΗ - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Adtralza Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

adtralza

leo pharma a/s - tralokinumab - Δερματίτιδα, Ατοπική - Άλλα δερματολογικά παρασκευάσματα - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Dupixent Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Παράγοντες για δερματίτιδα, εξαιρουμένων των κορτικοστεροειδών - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Rasilez Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

rasilez

noden pharma dac - αλισκιρένη - Υπέρταση - Παράγοντες που δρουν στο σύστημα ρενίνης-αγγειοτενσίνης - Θεραπεία της ιδιοπαθούς υπέρτασης.

Protopic Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

protopic

leo pharma a/s - tacrolimus - Δερματίτιδα, Ατοπική - Άλλα δερματολογικά παρασκευάσματα - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. συμβαίνουν τέσσερις ή περισσότερες φορές ανά έτος) που είχαν μια πρώτη απάντηση σε ένα μέγιστο έξι εβδομάδες θεραπεία δύο φορές την ημέρα αλοιφή τακρόλιμους (βλάβες εκκαθαριστεί, σχεδόν καθαρίσει ή ελαφρώς επηρεάζονται).

BETNOVATE 0.1% W/W CREAM Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

betnovate 0.1% w/w cream

glaxosmithkline (ireland) limited (0000010774) 12 riverwalk, citywest business campus, dublin, dublin 24 - betamethasone valerate - cream - 0.1% w/w - betamethasone valerate (0002152445) 0,122% w/w - betamethasone

MEDOBETA 0.1% W/W OINTMENT Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

medobeta 0.1% w/w ointment

medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - betamethasone valerate - ointment - 0.1% w/w - betamethasone valerate (0002152445) 1,22mg - betamethasone

MEDOBETA 0.1% W/W CREAM Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

medobeta 0.1% w/w cream

medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - betamethasone valerate - cream - 0.1% w/w - betamethasone valerate (0002152445) 1mg base - betamethasone

VENOFER 100MG/5ML SOLUTION FOR INJECTION Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

venofer 100mg/5ml solution for injection

the star medicines importers co. ltd (0000003109) 10 loukis akritas str, lemesos, 3601, 50151 - saccharated iron oxide - solution for injection - 100mg/5ml - saccharated iron oxide (0008047674) 100mg - saccharated iron oxide